{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T16:40:25Z","timestamp":1781023225295,"version":"3.54.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003491","name":"Herlev Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00392-022-02016-z","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T17:02:50Z","timestamp":1649437370000},"page":"215-226","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical cardiovascular phenotypes and the pattern of future events in patients with type 2 diabetes"],"prefix":"10.1007","volume":"112","author":[{"given":"Mariam Elmegaard","family":"Malik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Blanche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Madelaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bochra","family":"Zareini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Lamberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren Lund","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"K\u00f8ber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Torp-Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Gislason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Schou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,8]]},"reference":[{"key":"2016_CR1","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1007\/s00125-018-4630-2","volume":"61","author":"B Zinman","year":"2018","unstructured":"Zinman B, Inzucchi SE, Wanner C et al (2018) Empagliflozin in women with type 2 diabetes and cardiovascular disease\u2014an analysis of EMPA-REG OUTCOME(R). Diabetologia 61:1522\u20131527","journal-title":"Diabetologia"},{"key":"2016_CR2","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128","journal-title":"N Engl J Med"},{"key":"2016_CR3","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","volume":"137","author":"KW Mahaffey","year":"2018","unstructured":"Mahaffey KW, Neal B, Perkovic V et al (2018) Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation 137:323\u2013334","journal-title":"Circulation"},{"key":"2016_CR4","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","volume":"138","author":"K Radholm","year":"2018","unstructured":"Radholm K, Figtree G, Perkovic V et al (2018) Canagliflozin and heart failure in type 2 diabetes mellitus. Circulation 138:458\u2013468","journal-title":"Circulation"},{"key":"2016_CR5","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392:1519\u20131529","journal-title":"Lancet"},{"key":"2016_CR6","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, Rorth R, Jhund PS et al (2019) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 7:776\u2013785","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2016_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire DK, Shih WJ, Cosentino F et al (2021) Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol 6:148\u2013158","journal-title":"JAMA Cardiol"},{"key":"2016_CR8","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein HC, Sattar N, Rosenstock J et al (2021) Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med 385:896\u2013907","journal-title":"N Engl J Med"},{"key":"2016_CR9","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL et al (2021) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 9:653\u2013662","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2016_CR10","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jama.2016.10260","volume":"316","author":"KB Margulies","year":"2016","unstructured":"Margulies KB, Hernandez AF, Redfield MM et al (2016) Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 316:500\u2013508","journal-title":"JAMA"},{"key":"2016_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ejhf.657","volume":"19","author":"A Jorsal","year":"2017","unstructured":"Jorsal A, Kistorp C, Holmager P et al (2017) Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 19:69\u201377","journal-title":"Eur J Heart Fail"},{"key":"2016_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2337\/cd18-0105","volume":"37","author":"DA American","year":"2019","unstructured":"American DA (2019) Standards of medical care in diabetes-2019 abridged for primary care providers. Clin Diabetes 37:11\u201334","journal-title":"Clin Diabetes"},{"key":"2016_CR13","unstructured":"Cosentino F, Grant PJ, Aboyans V et al (2019) ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41(2):255\u2013323"},{"key":"2016_CR14","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.2337\/dc20-S009","volume":"43","author":"American Diabetes A","year":"2020","unstructured":"American Diabetes A (2020) 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care 43:S98\u2013S110","journal-title":"Diabetes Care"},{"key":"2016_CR15","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.2337\/dc20-S010","volume":"43","author":"American Diabetes A","year":"2020","unstructured":"American Diabetes A (2020) 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2020. Diabetes Care 43:S111\u2013S134","journal-title":"Diabetes Care"},{"key":"2016_CR16","first-page":"441","volume":"53","author":"CB Pedersen","year":"2006","unstructured":"Pedersen CB, Gotzsche H, Moller JO, Mortensen PB (2006) The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull 53:441\u2013449","journal-title":"Dan Med Bull"},{"key":"2016_CR17","first-page":"798","volume":"46","author":"A Pottegard","year":"2017","unstructured":"Pottegard A, Schmidt SAJ, Wallach-Kildemoes H, Sorensen HT, Hallas J, Schmidt M (2017) Data resource profile: the Danish National Prescription Registry. Int J Epidemiol 46:798\u2013798f","journal-title":"Int J Epidemiol"},{"key":"2016_CR18","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/CLEP.S91125","volume":"7","author":"M Schmidt","year":"2015","unstructured":"Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT (2015) The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 7:449\u2013490","journal-title":"Clin Epidemiol"},{"key":"2016_CR19","unstructured":"R: A language and environment for statistical computing. Vienna, Austria: R Development Core Team"},{"key":"2016_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1158\/1078-0432.CCR-12-1619","volume":"19","author":"C Schmoor","year":"2013","unstructured":"Schmoor C, Schumacher M, Finke J, Beyersmann J (2013) Competing risks and multistate models. Clin Cancer Res 19:12\u201321","journal-title":"Clin Cancer Res"},{"key":"2016_CR21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s11886-019-1197-6","volume":"21","author":"DS Dhindsa","year":"2019","unstructured":"Dhindsa DS, Mehta A, Sandesara PB, Thobani A, Brandt S, Sperling LS (2019) Strategies for appropriate selection of SGLT2-i vs. GLP1-RA in persons with diabetes and cardiovascular disease. Curr Cardiol Rep 21:100","journal-title":"Curr Cardiol Rep"},{"key":"2016_CR22","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1016\/j.jacc.2018.09.020","volume":"72","author":"SR Das","year":"2018","unstructured":"Das SR, Everett BM, Birtcher KK et al (2018) 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on expert consensus decision pathways. J Am Coll Cardiol 72:3200\u20133223","journal-title":"J Am Coll Cardiol"},{"key":"2016_CR23","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1016\/j.jacc.2018.07.071","volume":"72","author":"JD Newman","year":"2018","unstructured":"Newman JD, Vani AK, Aleman JO, Weintraub HS, Berger JS, Schwartzbard AZ (2018) The changing landscape of diabetes therapy for cardiovascular risk reduction: JACC state-of-the-art review. J Am Coll Cardiol 72:1856\u20131869","journal-title":"J Am Coll Cardiol"},{"key":"2016_CR24","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/ejhf.1432","volume":"21","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, DeMets DL, Inzucchi SE et al (2019) A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail 21:665\u2013675","journal-title":"Eur J Heart Fail"},{"key":"2016_CR25","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/ejhf.1548","volume":"21","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, DeMets DL, Inzucchi SE et al (2019) The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. Eur J Heart Fail 21:1402\u20131411","journal-title":"Eur J Heart Fail"},{"key":"2016_CR26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ahj.2018.01.012","volume":"200","author":"SD Wiviott","year":"2018","unstructured":"Wiviott SD, Raz I, Bonaca MP et al (2018) The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. Am Heart J 200:83\u201389","journal-title":"Am Heart J"},{"key":"2016_CR27","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/j.jacc.2009.08.019","volume":"54","author":"SM Dunlay","year":"2009","unstructured":"Dunlay SM, Redfield MM, Weston SA et al (2009) Hospitalizations after heart failure diagnosis a community perspective. J Am Coll Cardiol 54:1695\u20131702","journal-title":"J Am Coll Cardiol"},{"key":"2016_CR28","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3389\/fgene.2017.00216","volume":"8","author":"T Head","year":"2017","unstructured":"Head T, Daunert S, Goldschmidt-Clermont PJ (2017) The aging risk and atherosclerosis: a fresh look at arterial homeostasis. Front Genet 8:216","journal-title":"Front Genet"},{"key":"2016_CR29","first-page":"109","volume":"13","author":"X Dai","year":"2016","unstructured":"Dai X, Busby-Whitehead J, Forman DE, Alexander KP (2016) Stable ischemic heart disease in the older adults. J Geriatr Cardiol 13:109\u2013114","journal-title":"J Geriatr Cardiol"},{"key":"2016_CR30","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1161\/STROKEAHA.116.016022","volume":"48","author":"K Adelborg","year":"2017","unstructured":"Adelborg K, Szepligeti S, Sundboll J et al (2017) Risk of stroke in patients with heart failure: a population-based 30-year cohort study. Stroke 48:1161\u20131168","journal-title":"Stroke"},{"key":"2016_CR31","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1161\/STROKEAHA.111.628479","volume":"42","author":"KG Haeusler","year":"2011","unstructured":"Haeusler KG, Laufs U, Endres M (2011) Chronic heart failure and ischemic stroke. Stroke 42:2977\u20132982","journal-title":"Stroke"},{"key":"2016_CR32","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ahj.2005.10.018","volume":"152","author":"BJ Witt","year":"2006","unstructured":"Witt BJ, Brown RD Jr, Jacobsen SJ et al (2006) Ischemic stroke after heart failure: a community-based study. Am Heart J 152:102\u2013109","journal-title":"Am Heart J"},{"key":"2016_CR33","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.cardfail.2007.01.009","volume":"13","author":"BJ Witt","year":"2007","unstructured":"Witt BJ, Gami AS, Ballman KV et al (2007) The incidence of ischemic stroke in chronic heart failure: a meta-analysis. J Card Fail 13:489\u2013496","journal-title":"J Card Fail"},{"key":"2016_CR34","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1007\/s00125-019-4926-x","volume":"62","author":"T Ohkuma","year":"2019","unstructured":"Ohkuma T, Komorita Y, Peters SAE, Woodward M (2019) Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals. Diabetologia 62:1550\u20131560","journal-title":"Diabetologia"},{"key":"2016_CR35","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1161\/CIR.0000000000000343","volume":"132","author":"JG Regensteiner","year":"2015","unstructured":"Regensteiner JG, Golden S, Huebschmann AG et al (2015) Sex differences in the cardiovascular consequences of diabetes mellitus: a scientific statement from the American Heart Association. Circulation 132:2424\u20132447","journal-title":"Circulation"},{"key":"2016_CR36","doi-asserted-by":"publisher","first-page":"6039356","DOI":"10.1155\/2017\/6039356","volume":"2017","author":"P Ballotari","year":"2017","unstructured":"Ballotari P, Venturelli F, Greci M, Giorgi Rossi P, Manicardi V (2017) Sex differences in the effect of type 2 diabetes on major cardiovascular diseases: results from a population-based study in Italy. Int J Endocrinol 2017:6039356","journal-title":"Int J Endocrinol"},{"key":"2016_CR37","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.2337\/dc06-2558","volume":"30","author":"A Avogaro","year":"2007","unstructured":"Avogaro A, Giorda C, Maggini M et al (2007) Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care 30:1241\u20131247","journal-title":"Diabetes Care"},{"key":"2016_CR38","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1001\/jama.1988.03410230074031","volume":"260","author":"RD Abbott","year":"1988","unstructured":"Abbott RD, Donahue RP, Kannel WB, Wilson PW (1988) The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study. JAMA 260:3456\u20133460","journal-title":"JAMA"},{"key":"2016_CR39","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","volume":"139","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I et al (2019) Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation 139:2022\u20132031","journal-title":"Circulation"},{"key":"2016_CR40","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1161\/CIRCULATIONAHA.120.047965","volume":"143","author":"CV Dave","year":"2021","unstructured":"Dave CV, Kim SC, Goldfine AB, Glynn RJ, Tong A, Patorno E (2021) Risk of cardiovascular outcomes in patients with type 2 diabetes after addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA therapy. Circulation 143:770\u2013779","journal-title":"Circulation"},{"key":"2016_CR41","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1161\/CIRCULATIONAHA.121.057934","volume":"145","author":"CSP Lam","year":"2022","unstructured":"Lam CSP, Ramasundarahettige C, Branch KRH et al (2022) Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial. Circulation 145:565\u2013574","journal-title":"Circulation"},{"key":"2016_CR42","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","volume":"29","author":"M Schmidt","year":"2014","unstructured":"Schmidt M, Pedersen L, Sorensen HT (2014) The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 29:541\u2013549","journal-title":"Eur J Epidemiol"},{"key":"2016_CR43","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.ejheart.2008.05.006","volume":"10","author":"T Kumler","year":"2008","unstructured":"Kumler T, Gislason GH, Kirk V et al (2008) Accuracy of a heart failure diagnosis in administrative registers. Eur J Heart Fail 10:658\u2013660","journal-title":"Eur J Heart Fail"},{"key":"2016_CR44","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1210\/jc.2015-2696","volume":"100","author":"KH Mikkelsen","year":"2015","unstructured":"Mikkelsen KH, Knop FK, Frost M, Hallas J, Pottegard A (2015) Use of antibiotics and risk of type 2 diabetes: a population-based case-control study. J Clin Endocrinol Metab 100:3633\u20133640","journal-title":"J Clin Endocrinol Metab"},{"key":"2016_CR45","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.107.720847","volume":"117","author":"TK Schramm","year":"2008","unstructured":"Schramm TK, Gislason GH, Kober L et al (2008) Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 117:1945\u20131954","journal-title":"Circulation"},{"key":"2016_CR46","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/eurheartj\/ehr077","volume":"32","author":"TK Schramm","year":"2011","unstructured":"Schramm TK, Gislason GH, Vaag A et al (2011) Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 32:1900\u20131908","journal-title":"Eur Heart J"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-022-02016-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-022-02016-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-022-02016-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T21:09:11Z","timestamp":1675544951000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-022-02016-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,8]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["2016"],"URL":"https:\/\/doi.org\/10.1007\/s00392-022-02016-z","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,8]]},"assertion":[{"value":"6 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"All authors declare\nthat they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}